oxonic acid has been researched along with Laryngeal Neoplasms in 21 studies
Oxonic Acid: Antagonist of urate oxidase.
Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium)." | 3.80 | Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study. ( Higashino, M; Ichihara, S; Kawata, R; Lee, K; Nishikawa, S; Uesugi, Y, 2014) |
| "Eligible patients had T1b or T2 glottic squamous cell carcinomas." | 2.80 | Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. ( Fujimoto, Y; Hiramatsu, M; Itoh, J; Itoh, Y; Kawamura, M; Kimura, K; Kubota, S; Naganawa, S; Nakahara, R; Okada, T; Shibata, T, 2015) |
| "Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established." | 2.72 | A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. ( Inoue, T; Kiba, T; Murata, H; Nagata, K; Nagata, M; Shimode, Y; Tomoda, K; Tsuji, H; Yamashita, T; Yukawa, H, 2006) |
| " We analyzed the clinical response, survival rate, acute adverse events, and late swallowing toxicity." | 1.51 | Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma. ( Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019) |
| "In resectable advanced laryngeal cancer, S-1 adjuvant chemotherapy is an effective and feasible treatment option to control distant metastases following reduced RADPLAT." | 1.38 | Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer. ( Endo, K; Kondo, S; Murono, S; Wakisaka, N; Yoshizaki, T, 2012) |
| "CCRT is the mainstay of treatment for laryngeal cancer in our department, given our goals of achieving organ and functional preservation, as well as radical cure." | 1.37 | [Laryngeal cancer treatment outcomes in our department]. ( Akiyama, R; Egawa, S; Hayashi, T; Ikeda, K; Ikenoya, Y; Sanbe, T; Shimane, T; Sugimoto, A; Uzuki, A, 2011) |
| "We herein report our examination of 20 laryngeal cancer cases receiving concomitant therapy with S-1, Nedaplatin, and radiation (hereinafter, referred to as SN therapy) in our department from April 2005 to December 2008." | 1.36 | [Effectiveness of concomitant therapy with S-1, nedaplatin, and radiation for laryngeal cancer]. ( Furuya, A; Kaburagi, A; Kamakazu, K; Kobayashi, S; Monden, T; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2010) |
| " Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case." | 1.35 | [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. ( Furuya, A; Kobayashi, S; Monden, T; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2009) |
| "We report two head and neck cancer patients who responded to TS-1." | 1.32 | [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1]. ( Horiuchi, C; Kagesato, Y; Kawai, S; Mikami, Y; Mochimatsu, I; Tanigaki, Y; Tsukuda, M, 2003) |
| "A patient with advanced recurrent laryngeal cancer complicated with cervical lymph node metastasis was successfully treated with chemoradiotherapy with an oral anticancer drug, TS-1." | 1.32 | [A case of lymph node metastasis after total laryngectomy successfully treated with chemoradiotherapy with TS-1]. ( Suzuki, S; Yoshihara, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sano, D | 2 |
| Tanabe, T | 1 |
| Kubota, A | 3 |
| Miyamoto, S | 1 |
| Tanigaki, Y | 4 |
| Okami, K | 1 |
| Komatsu, M | 2 |
| Ikoma, R | 1 |
| Suzuki, K | 2 |
| Akazawa, Y | 1 |
| Kobayashi, S | 3 |
| Yamada, Y | 1 |
| Oridate, N | 3 |
| Kitani, Y | 2 |
| Furukawa, M | 1 |
| Hori, Y | 1 |
| Nakayama, Y | 1 |
| Nonaka, T | 1 |
| Mizoguchi, N | 1 |
| Hatakeyama, H | 1 |
| Kimura, K | 2 |
| Itoh, Y | 2 |
| Okada, T | 2 |
| Kubota, S | 2 |
| Kawamura, M | 2 |
| Nakahara, R | 2 |
| Oie, Y | 1 |
| Kozai, Y | 1 |
| Takase, Y | 1 |
| Tsuzuki, H | 1 |
| Nishio, N | 1 |
| Hiramatsu, M | 2 |
| Fujimoto, Y | 2 |
| Mizutani, T | 1 |
| Hirakawa, A | 1 |
| Naganawa, S | 2 |
| Okuda, H | 1 |
| Ohnishi, M | 1 |
| Takahashi, H | 1 |
| Takagi, C | 1 |
| Takada, N | 1 |
| Ohashi, T | 1 |
| Higashino, M | 1 |
| Kawata, R | 1 |
| Lee, K | 1 |
| Nishikawa, S | 1 |
| Ichihara, S | 1 |
| Uesugi, Y | 1 |
| Taguchi, T | 2 |
| Takahashi, M | 1 |
| Nishimura, G | 1 |
| Shiono, O | 1 |
| Sakuma, Y | 1 |
| Taguri, M | 1 |
| Hata, M | 1 |
| Itoh, J | 1 |
| Shibata, T | 1 |
| Shimane, T | 3 |
| Mori, T | 2 |
| Ono, T | 2 |
| Monden, T | 2 |
| Furuya, A | 2 |
| Sanbe, T | 4 |
| Suzaki, H | 3 |
| Abo, H | 1 |
| Tsukuda, M | 3 |
| Matsuda, H | 1 |
| Horiuchi, C | 2 |
| Watanabe, M | 1 |
| Niho, T | 1 |
| Kaburagi, A | 1 |
| Kamakazu, K | 1 |
| Nakayama, M | 1 |
| Hayakawa, K | 1 |
| Okamoto, M | 1 |
| Niibe, Y | 1 |
| Ishiyama, H | 1 |
| Kotani, S | 1 |
| Nonoshita, T | 1 |
| Shioyama, Y | 1 |
| Nakamura, K | 1 |
| Nakashima, T | 1 |
| Ohga, S | 1 |
| Yoshitake, T | 1 |
| Ohnishi, K | 1 |
| Terashima, K | 1 |
| Asai, K | 1 |
| Honda, H | 1 |
| Kuratomi, Y | 1 |
| Satoh, S | 1 |
| Monji, M | 1 |
| Yokogawa, K | 1 |
| Shimazu, R | 1 |
| Tokumaru, S | 1 |
| Inokuchi, A | 1 |
| Morimoto, M | 1 |
| Takemura, H | 1 |
| Yui, T | 1 |
| Suzuki, T | 1 |
| Egawa, S | 1 |
| Akiyama, R | 1 |
| Ikenoya, Y | 1 |
| Uzuki, A | 1 |
| Sugimoto, A | 1 |
| Hayashi, T | 1 |
| Ikeda, K | 1 |
| Wakisaka, N | 1 |
| Kondo, S | 1 |
| Endo, K | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Mikami, Y | 1 |
| Kawai, S | 1 |
| Kagesato, Y | 1 |
| Mochimatsu, I | 1 |
| Suzuki, S | 1 |
| Yoshihara, T | 1 |
| Tsuji, H | 2 |
| Nagata, M | 2 |
| Inoue, T | 2 |
| Minami, T | 1 |
| Iwai, H | 1 |
| Ohnishi, S | 1 |
| Yukawa, H | 2 |
| Ogura, M | 1 |
| Yamashita, T | 2 |
| Nagata, K | 2 |
| Kiba, T | 1 |
| Shimode, Y | 1 |
| Murata, H | 1 |
| Tomoda, K | 1 |
| Ikeda, Y | 1 |
| Yabuki, K | 1 |
| Mitake, D | 1 |
| Ishitoya, J | 1 |
5 trials available for oxonic acid and Laryngeal Neoplasms
| Article | Year |
|---|---|
Phase II study of concurrent chemoradiotherapy with S-1 in patients with stage II (T2N0M0) squamous cell carcinoma of the Pharynx or Larynx.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combination | 2014 |
Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Drug Combinations; Fem | 2015 |
Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administr | 2010 |
[Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deglutit | 2006 |
A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma.
Topics: Adult; Aged; Dermatitis; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Combi | 2006 |
16 other studies available for oxonic acid and Laryngeal Neoplasms
| Article | Year |
|---|---|
Addition of S-1 to radiotherapy for treatment of T2N0 glottic cancer: Results of the multiple-center retrospective cohort study in Japan with a propensity score analysis.
Topics: Adult; Aged; Aged, 80 and over; Drug Combinations; Female; Glottis; Humans; Japan; Laryngeal Neoplas | 2019 |
Impact of combined modality treatment with radiotherapy and S-1 on T2N0 laryngeal cancer: Possible improvement in survival through the prevention of second primary cancer and distant metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combination | 2017 |
Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Combinations; Fema | 2018 |
Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2019 |
Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Drug Combina | 2014 |
[Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combination | 2009 |
[Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
[Effectiveness of concomitant therapy with S-1, nedaplatin, and radiation for laryngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combina | 2010 |
Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2010 |
[A comparative study of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or laryngeal cancer].
Topics: Aged; Aged, 80 and over; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; La | 2010 |
[Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2010 |
[Laryngeal cancer treatment outcomes in our department].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; F | 2011 |
Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
[Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; He | 2003 |
[A case of lymph node metastasis after total laryngectomy successfully treated with chemoradiotherapy with TS-1].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Laryngeal Neoplasms; Laryngectomy; Lymph | 2003 |
[Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; D | 2008 |